Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04569344 · ClinicalTrials.gov registry record
COVID-19 and Venous Thromboembolism Risk
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 398,530
- Enrollment target
NCT04569344 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 398,530 participants.
The verdict
NCT04569344 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 398,530 participants
- Enrollment target
Study Summary
Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly reported in patients with severe Covid-19. The aim of this study is evaluate the risk of VTE related to Covid-19 infection in a real-world community-based population.
Interventions
- OTHER Laboratory test positive for SARS-CoV-2 virus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398,530 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2022-06-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04569344
The ClinicalTrials.gov registry entry for NCT04569344 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 398,530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Laboratory test positive for SARS-CoV-2 virus is the first listed.
NCT04569344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04569344 about?
NCT04569344 is a clinical study titled "COVID-19 and Venous Thromboembolism Risk". Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly reported in patients with severe Covid-19. The aim of this study is evalu...
What is the current status of trial NCT04569344?
This trial is currently completed. The enrollment target is 398,530 participants. The study started on 2020-01-01. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT04569344?
The interventions under investigation include: Laboratory test positive for SARS-CoV-2 virus (OTHER).
Who is sponsoring clinical trial NCT04569344?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.